About
BrightHeart is a Paris-based leader in artificial intelligence solutions focused on obstetrics and pediatric cardiology, particularly in fetal heart assessment. The company has developed an AI-powered medical software that enhances the detection of congenital heart defects (CHDs), which often go undetected during routine prenatal ultrasounds. Their flagship product is a digital screening tool that utilizes AI to provide comprehensive and standardized fetal heart assessments during anatomy scans. This software offers real-time analysis and feedback to clinicians, streamlining workflows and improving the accuracy of screenings. By flagging potential structural abnormalities, BrightHeart's technology helps clinicians identify high-risk cases more reliably. BrightHeart has received multiple FDA 510(k) clearances and has implemented a Predetermined Change Control Plan (PCCP) for rapid AI improvements. Their solutions integrate seamlessly into existing ultrasound workflows, making expert-level ultrasound care accessible in various clinical settings. The company aims to enhance early detection of CHDs, ultimately improving outcomes for affected children worldwide.
Technologies
Keywords
Company Information
-
Employees 20
-
Founded 2020
-
Annual Revenue $3444000
-
Total Funding $2143620
Location
11 Boulevard Haussmann, Paris, Ile-de-France, France, 75009